NO20091545L - Fremgangsmåte for levering av medikament for ben-anabolt protein - Google Patents

Fremgangsmåte for levering av medikament for ben-anabolt protein

Info

Publication number
NO20091545L
NO20091545L NO20091545A NO20091545A NO20091545L NO 20091545 L NO20091545 L NO 20091545L NO 20091545 A NO20091545 A NO 20091545A NO 20091545 A NO20091545 A NO 20091545A NO 20091545 L NO20091545 L NO 20091545L
Authority
NO
Norway
Prior art keywords
protein drug
bone anabolic
delivering bone
anabolic protein
delivering
Prior art date
Application number
NO20091545A
Other languages
English (en)
Other versions
NO344885B1 (no
Inventor
Cecil Richard Lyttle
Michael J Dey
Nathalie Mondoly
Benedicte Rigaud
Bart Henderson
Original Assignee
Ipsen Pharma Sas
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39430237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091545(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ipsen Pharma Sas, Radius Health Inc filed Critical Ipsen Pharma Sas
Publication of NO20091545L publication Critical patent/NO20091545L/no
Publication of NO344885B1 publication Critical patent/NO344885B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO20091545A 2006-10-03 2009-04-20 En stabil sammensetning omfattende et benanabolt protein, nemlig en PTHrP-analog, og anvendelser derav NO344885B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84896006P 2006-10-03 2006-10-03
PCT/US2007/021216 WO2008063279A2 (en) 2006-10-03 2007-10-03 A stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof

Publications (2)

Publication Number Publication Date
NO20091545L true NO20091545L (no) 2009-05-27
NO344885B1 NO344885B1 (no) 2020-06-15

Family

ID=39430237

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091545A NO344885B1 (no) 2006-10-03 2009-04-20 En stabil sammensetning omfattende et benanabolt protein, nemlig en PTHrP-analog, og anvendelser derav

Country Status (28)

Country Link
US (1) US8148333B2 (no)
EP (2) EP2957278B1 (no)
JP (1) JP5375611B2 (no)
KR (4) KR20170067906A (no)
CN (2) CN101578093B (no)
AU (1) AU2007322334B2 (no)
BR (2) BRPI0719821B8 (no)
CA (1) CA2664734C (no)
CY (1) CY1119198T1 (no)
DK (2) DK2957278T3 (no)
ES (2) ES2637283T3 (no)
FR (1) FR23C1024I2 (no)
HR (1) HRP20171217T1 (no)
IL (1) IL197926A (no)
LT (1) LT2957278T (no)
LU (1) LUC00309I2 (no)
MX (1) MX2009003569A (no)
NL (1) NL301235I2 (no)
NO (1) NO344885B1 (no)
NZ (1) NZ576682A (no)
PL (1) PL2957278T3 (no)
PT (2) PT2073789T (no)
RS (1) RS56164B1 (no)
RU (1) RU2506070C2 (no)
SG (1) SG175580A1 (no)
SI (1) SI2957278T1 (no)
UA (1) UA98776C2 (no)
WO (1) WO2008063279A2 (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803770B2 (en) * 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
HUE030072T2 (en) 2010-05-12 2017-04-28 Radius Health Inc Therapeutic prescriptions
US9133182B2 (en) 2010-09-28 2015-09-15 Radius Health, Inc. Selective androgen receptor modulators
EP2472329B1 (en) 2010-12-31 2013-06-05 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2472328B1 (en) 2010-12-31 2013-06-19 Rohm and Haas Electronic Materials LLC Coating compositions for use with an overcoated photoresist
EP2699252B1 (en) 2011-04-22 2017-10-25 Radius Health, Inc. Method of drug delivery for pth, pthrp and related peptides
KR20150116467A (ko) 2011-06-07 2015-10-15 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
KR102143482B1 (ko) * 2011-11-30 2020-08-11 쓰리엠 이노베이티브 프로퍼티즈 컴파니 펩티드 치료제 및 아미노산을 포함하는 마이크로니들 장치, 이의 제조 및 사용 방법
ES3055185T3 (en) 2014-03-28 2026-02-10 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
CA2977812A1 (en) * 2015-03-03 2016-09-09 Radius Health, Inc. Uses of pthrp analogue in reducing fracture risk
KR20250152679A (ko) 2015-04-29 2025-10-23 래디어스 파마슈티컬스, 인코포레이티드 암을 치료하는 방법
CN108025042A (zh) * 2015-07-06 2018-05-11 董正欣 PTHrP类似物的新型制剂
CN106479329A (zh) 2015-08-31 2017-03-08 罗门哈斯电子材料有限责任公司 与外涂布光致抗蚀剂一起使用的涂料组合物
KR20180067573A (ko) * 2015-10-09 2018-06-20 라디우스 헬쓰, 인코포레이티드 PTHrP 유사체의 제형, 이의 경피 패취, 및 이의 용도
US10568937B2 (en) 2016-04-18 2020-02-25 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
MX389702B (es) 2016-06-22 2025-03-20 Ellipses Pharma Ltd Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
CA3045458A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
WO2019232283A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
MX2020013713A (es) 2018-07-04 2021-03-02 Radius Pharmaceuticals Inc Formas polimorficas de rad1901-2hcl.
EP3924328A1 (en) 2019-02-12 2021-12-22 Radius Pharmaceuticals, Inc. Processes and compounds
EP4110371A1 (en) 2020-01-24 2023-01-04 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003105772A2 (en) * 2002-06-13 2003-12-24 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents
US20050282749A1 (en) * 2000-09-18 2005-12-22 Henriksen Dennis B Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US5589452A (en) 1992-07-14 1996-12-31 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US5821225A (en) 1992-07-14 1998-10-13 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia comprising administration of modified PTH or PTHrp
EP0679088B1 (en) 1992-09-29 2002-07-10 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
WO1995002610A1 (en) 1993-07-13 1995-01-26 Syntex (U.S.A.) Inc. Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US6544949B1 (en) 1995-07-13 2003-04-08 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5969095A (en) 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
CN1204262A (zh) * 1995-10-17 1999-01-06 曼海姆泊灵格股份公司 稳定的含甲状旁腺激素的药物给药剂型
TW505654B (en) 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
US6136784A (en) 1997-01-08 2000-10-24 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
HRP20000109A2 (en) 1997-09-09 2001-02-28 Hoffmann La Roche FRACTURE HEALING USING PTHrP ANALOGS
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
CA2511966A1 (en) 2002-11-01 2004-07-22 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
CA2567056A1 (en) * 2004-05-10 2005-12-08 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7803770B2 (en) 2006-10-03 2010-09-28 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
BRPI0719821B8 (pt) 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282749A1 (en) * 2000-09-18 2005-12-22 Henriksen Dennis B Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2003105772A2 (en) * 2002-06-13 2003-12-24 Beth Israel Deaconess Medical Center, Inc. Analogs of parathyroid hormone and pth-related protein as bone anabolic agents

Also Published As

Publication number Publication date
DK2957278T3 (en) 2017-07-31
CA2664734A1 (en) 2008-05-29
PT2073789T (pt) 2019-07-31
AU2007322334B2 (en) 2011-12-22
CA2664734C (en) 2023-08-01
EP2957278B1 (en) 2017-05-17
FR23C1024I1 (fr) 2023-07-21
WO2008063279A9 (en) 2008-07-10
BRPI0719821B8 (pt) 2021-05-25
UA98776C2 (ru) 2012-06-25
LT2957278T (lt) 2017-09-11
KR20090083350A (ko) 2009-08-03
KR20180117738A (ko) 2018-10-29
PL2957278T3 (pl) 2017-10-31
NO344885B1 (no) 2020-06-15
CN102274492B (zh) 2014-11-26
CY1119198T1 (el) 2018-02-14
ES2739459T3 (es) 2020-01-31
KR20150020289A (ko) 2015-02-25
KR20170067906A (ko) 2017-06-16
RS56164B1 (sr) 2017-11-30
HRP20171217T1 (hr) 2017-10-20
NZ576682A (en) 2012-08-31
RU2506070C2 (ru) 2014-02-10
SI2957278T1 (sl) 2017-09-29
WO2008063279A3 (en) 2009-06-25
BRPI0719821B1 (pt) 2020-04-14
DK2073789T3 (da) 2019-08-05
EP2073789A2 (en) 2009-07-01
NL301235I2 (nl) 2023-08-31
SG175580A1 (en) 2011-11-28
CN101578093A (zh) 2009-11-11
IL197926A (en) 2014-08-31
IL197926A0 (en) 2011-08-01
EP2957278A1 (en) 2015-12-23
LUC00309I2 (no) 2025-09-22
US20100029556A1 (en) 2010-02-04
HK1214181A1 (en) 2016-07-22
EP2073789B1 (en) 2019-05-22
BRPI0722428A2 (pt) 2013-11-26
JP5375611B2 (ja) 2013-12-25
KR101512377B1 (ko) 2015-04-28
CN102274492A (zh) 2011-12-14
FR23C1024I2 (fr) 2024-06-14
RU2009116531A (ru) 2010-11-10
CN101578093B (zh) 2011-09-14
ES2637283T3 (es) 2017-10-11
MX2009003569A (es) 2009-08-25
AU2007322334A1 (en) 2008-05-29
EP2073789B8 (en) 2023-02-08
BRPI0719821A2 (pt) 2013-05-07
WO2008063279A2 (en) 2008-05-29
US8148333B2 (en) 2012-04-03
PT2957278T (pt) 2017-08-23
JP2010505835A (ja) 2010-02-25

Similar Documents

Publication Publication Date Title
NO20091545L (no) Fremgangsmåte for levering av medikament for ben-anabolt protein
DK2023958T4 (da) Farmaceutisk produkt til intraoral levering af nikotin omfattende trometamol som buffermiddel
BRPI0716982A2 (pt) mÉtodo e sistema para infusço controlada de substÂncia terapÊutica
DK3136030T3 (da) Fremgangsmåde til lyofilisering
EP2101745A4 (en) ADMINISTRATION OF MEDICINES
IL210883A0 (en) Drug delivery system and method of munufacturing thereof
BRPI0923808A2 (pt) Controle eletrônico de sistema de distribuição de fármaco
EP3323405C0 (en) SYSTEM AND METHOD FOR DISPENSING MEDICATION
BRPI1009418A2 (pt) nanocapsula de proteina, metodo de pdroduzir uma nanocapsula, e metodo de distribuir uma proteina
BRPI0921659A2 (pt) metodo e sistema para formar uma protese dentaria
PT2055308T (pt) Medicamento para promover a regeneração funcional de tecido danificado
EP2046213A4 (en) BONE FIXATION SYSTEM AND METHOD OF USE
EP2132133A4 (en) RELEASE OF PARTICULATE ACTIVE SUBSTANCES
IL211099A0 (en) Formulation for oral administration of proteins
CY2016053I2 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
BRPI0716790A2 (pt) Método e sistema para produzir uma prótese dentária
BRPI0907077A2 (pt) métodos e composições para administração oral de proteínas
EP2037738A4 (en) feeding method
DK3300743T3 (da) Fremgangsmåder til indgivelse af vaccine
DK2506712T3 (da) Morfinanderivater til behandling af lægemiddeloverdosering
EP2429987A4 (en) AMIDE COMPOUND, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
AP2008004593A0 (en) Antivral drugs for treatment of arenavirus infection
IL196228A0 (en) 4-hydroxythiobenzamide derivatives of drugs
ZA201007099B (en) Method for enhanced production of bone morphogenetic proteins
DK2296651T3 (da) 5-hydroxymethyl-oxazolidin-2-on-derivater til behandling af bakterielle intestinale sygdomme

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: IPSEN PHARMA SAS, US